Aclaris Therapeutics, Inc. — Form 8-K
Filed October 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 17/100
What the filing says
Aclaris Therapeutics issued 7,785,714 common shares at $3.29/share and 6,500,000 pre-funded warrants at $3.28999/warrant (with $0.00001 exercise price), closing October 28, 2026. Underwriters: Leerink Partners, Piper Sandler, Cantor Fitzgerald, and LifeSci Capital. Gross proceeds ~$25.6M; 60-day lock-up on insiders; warrants auto-exercise before fundamental transactions.
Why this rating
Offering size ~17% of $149M market cap—material dilution but routine equity raise for biotech. No major strategic change announced.
See more from October 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.